Blueberries Medical Corp. engages in the growth, cultivation, development, production, and supply of medicinal cannabis and cannabis-derived products in Latin America.
The last earnings update was 152 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Blueberries Medical. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Blueberries Medical's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Blueberries Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Blueberries Medical's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Blueberries Medical's earnings growth to the Canada market average as no estimate data is available.
Unable to compare Blueberries Medical's revenue growth to the Canada market average as no estimate data is available.
Unable to determine if Blueberries Medical is high growth as no earnings estimate data is available.
Unable to determine if Blueberries Medical is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Blueberries Medical's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Blueberries Medical's finances.
The net worth of a company is the difference between its assets and liabilities.
Blueberries Medical's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Blueberries Medical has no long term commitments.
This treemap shows a more detailed breakdown of
Blueberries Medical's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 1x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Patricio A. Stocker has been Chief Executive Officer of Blueberries Medical Corp. since March 2019. Dr. Stocker served as the Chief Executive Officer, President and Executive Director at PharmaCielo Ltd. Dr. Stocker has extensive management experience leading the development and implementation of businesses and strategies aligned to global, regional and local requirements, delivering high-quality results and strong profits. He joined PharmaCielo in 2015. He has held top management positions in the automotive industry with regional and country P&L responsibilities and is an experienced board member in multinational and family businesses. Dr. Stocker is responsible for Motorysa Group companies with revenues of US$100 million and 320 employees. He led a successful company restructuring process and negotiations with Mitsubishi Motors Corporation that generated an EBITDA growth close to 300% between 2011 and 2014, reaching an EBITDA of US$8.8 million in 2014. In 2012, he introduced the first electric vehicle fleets to Colombia, through partnerships with the three main electric supplier companies in the country. As director and head of Commercial Vehicles Latin America for Mercedes-Benz do Brasil Ltda., Dr. Stocker led global sales of trucks and bus chassis produced in Brazil, with direct responsibility for revenues of US$1.3 billion. He organized and led several major fleet negotiations dealing with first-time clients and led the separation process of Chrysler and Mercedes-Benz in Venezuela. He served as President and Chief Executive Officer of DaimlerChrysler Colombia S.A. He was responsible for the Colombian operation of Mercedes-Benz, Chrysler, Jeep, Dodge and Freightliner divisions, including wholesale and retail business, and the CKD assembly for bus chassis, with direct responsibility for revenues of US$125 million and over 350 employees, generating growth of 360% in sales volume between 2003 and 2005 while leading the strategic transformation of the company. He served as Chief Financial Officer of Mercedes-Benz Colombia S.A. and was head of Local Finance and Control, EvoBus Austria GmbH. Dr. Stocker is a member of the board of Cono S.A., an agricultural company headquartered in Argentina. He has previously served on the consultative board of Organización Empresarial Marcali as well as the boards of several Daimler AG affiliated companies in Latin America and the German-Colombian Commerce Chamber in Bogotá and was a member of the Young President Organization (YPO) in Bogotá and Sao Paulo. Dr. Stocker holds a PhD in Economics (Dr. oec.) and a Bachelor of Arts in Business Administration (lic. oec.), both from University of St. Gallen, Switzerland.
Insufficient data for Patricio to compare compensation growth.
Insufficient data for Patricio to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Blueberries Medical management team is less than 2 years, this suggests a new team.
Christian Guillermo Toro Ibler
Patricio A. Stocker
Chief Executive Officer
Chief Financial Officer
Camilo Villalba Gomez
Chief Operating Officer
Chief Marketing Officer
Board of Directors Tenure
Average tenure of the
board of directors in years:
The average tenure for the Blueberries Medical board of directors is less than 3 years, this suggests a new board.
Board of Directors
Christian Guillermo Toro Ibler
Paola Andrea Castañeda Beltran
Francisco Sole Franco
Fabio Valencia Cossio
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Blueberries Medical individual insiders in the past 3 months, but not in substantial volumes.
Blueberries Medical Corp. engages in the growth, cultivation, development, production, and supply of medicinal cannabis and cannabis-derived products in Latin America. The company offers medicinal-grade cannabis oil extracts and related products. Blueberries Medical Corp. is headquartered in Bogotá, Colombia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.